Tuberculosis treatment on the intensive care unit: ✅ There is no evidence to suggest that treatment of patients with tuberculosis on the intensive care unit should differ from👉 standard World Health Organization (2010) guidelines, consisting 👉of quadruple therapy, with: ✔️ isoniazid ✔️ rifampicin ✔️ pyrazinamide ✔️and ethambutol. ✅ This is dependent on enteral absorption – if impaired👉 🔶rifampicin 🔶 and isoniazid 👉👉 may be administered parenterally. ✅ Additional parenteral options include: ✔️ quinolones (moxifloxacin) ⏱️ an aminoglycoside (e.g. amikacin) 🔶 and linezolid. ✅ Therapeutic drug monitoring is advised, because of the variable 👉pharmacokinetics and pharmacodynamics. ✅ Additionally, some drugs (rifampicin) 👉may adhere to the nasogastric tube and be preferentially👉 administered intravenously while the patient is on the intensive 👉care unit. ✅ Management of drugresistant tuberculosis, rates of which are low (<15%) 👈among patients admitted to the intensive care unit, is complex and requires the involvement of 👉infectious diseases clinicians (Erbes et al, 2006; Lee et al, 2011). ✅ Toxicity and drug interactions should be carefully monitored for. ✅ Specifically, interactions with rifampicin are widespread, because of its inhibition of cytochrome PY450. ✅ Rifampicin will interact with the following drugs which are commonly used on intensive care units: morphine, fentanyl, midazolam, phenytoin, corticosteroids and antifungals.